RT Journal Article
SR Electronic
T1 Assessing the Impact of COVID-19 on Multimorbidity: Insights from Structural Equation Modeling in Colombia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.11.24313500
DO 10.1101/2024.09.11.24313500
A1 Porras-Ramírez, A
A1 Rico-Mendoza, A
A1 Campos-Maya, A
A1 Cardenas-Sanchez, J
A1 Penagos-Lopez, D
A1 Gomez-Puentes, A
A1 Delgado-Quiroz, N
A1 Guarin-Muñoz, L
A1 Ortiz-Elejalde, J
YR 2024
UL http://medrxiv.org/content/early/2024/09/13/2024.09.11.24313500.abstract
AB Background Multimorbidity, the coexistence of multiple chronic diseases, poses significant challenges for healthcare systems worldwide. This study aims to assess the situation of multimorbidity in Colombia using structural equation models and to characterize multimorbidity by sex, age group, region, and health insurance regime between 2019 and 2023.Methods We conducted a cross-sectional analytical study utilizing data from the Individual Health Service Provision Registry (RIPS) and other national databases, including the Unit of Payment by Capitation (UPC) Sufficiency Study Database. Structural equation models were employed to identify and analyze multimorbidity clusters among patients with two or more chronic diseases.Results The study revealed a multimorbidity prevalence of 61.5% in the general population. Hypertension emerged as the most prevalent chronic condition, frequently associated with diabetes and chronic kidney disease. Multimorbidity was more common in women and individuals affiliated with the contributory insurance regime. The study also identified significant variations in multimorbidity prevalence across different regions and age groups.Conclusions Multimorbidity is a prevalent issue in Colombia, with substantial variations by sex, age, and insurance regime. These findings underscore the need for tailored healthcare strategies to address the diverse needs of multimorbid patients. The results provide critical insights for health service planning and management, emphasizing the importance of continued research and policy development to mitigate the burden of chronic diseases and multimorbidity in Colombia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data used for the production of the research are taken from public data sources, do not require prior authorization for their use and are freely available. Does not require ethics committee approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data used for the production of the research are taken from public data sources, do not require prior authorization for their use and are freely available. Data taken from: https://www.sispro.gov.co/Pages/Home.aspx https://www.sispro.gov.co/Pages/Home.aspx